Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Matthias Christgen

20PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Foetal development and medicinePredictive and prognostic markersCancer diagnosisCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

Sort by Publication Date:
|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Apr 23, 2026
Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab-soravtansine therapy.

|Nov 27, 2025
Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP<sup>®</sup>).

Alexander Scheiter, Sven Mattern, Verena Gassenmaier

|Nov 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Sep 05, 2025
NMD-insensitive CDH1 mutation as a mechanism for retained E-cadherin protein expression in lobular carcinoma in situ (LCIS).

Matthias Christgen, Stephan Bartels, Hans Kreipe

Pageof 4

Frequent Collaborators

7 joint publications

Stephan Bartels

6 joint publications

Monika K Graeser

6 joint publications

Oleg Gluz

6 joint publications

Sherko Kümmel

6 joint publications

Nadia Harbeck

4 joint publications

Isabel Grote

3 joint publications

Ulrike Nitz

3 joint publications

Kerstin Luedtke-Heckenkamp

3 joint publications

Helmut Forstbauer

2 joint publications

Hans Holger Fischer

Frequent Collaborators

7 joint publications

Stephan Bartels

6 joint publications

Monika K Graeser

6 joint publications

Oleg Gluz

6 joint publications

Sherko Kümmel